A significant change in serum leptin level and no change in homocysteine were observed
with ibandronate treatment. No correlation of homocysteine and leptin was found with bone …

Osteoporosis is a condition in which bone mineral density is reduced due to altered bone
microstructure, which results in increased skeletal fragility and incidence of various types of …

Osteoporosis is a metabolic bone problem, also recognized as “the silent thief” because
there is slow bone loss, generally occurs over the years, and without any symptoms until the …

Thinness (low percentage of body fat, low body mass index [BMI], or low body weight) was
evaluated as a risk factor for low bone mineral density (BMD) or increased bone loss in a …

To examine the relationships between serum leptin and bone metabolism, we measured
bone mineral density (BMD) at the spine and the hip, fasting serum leptin, and osteocalcin …

Obesity is associated with both higher BONE MINERAL DENSITY (BMD) and plasma
LEPTIN concentration. Inconsistent data are available about the relationship of LEPTIN …

Objectives The aim of this study is to compare the antiresorptive effect of hormone therapy
and oral ibandronate in postmenopausal osteoporotic women by measuring bone mineral …

OBJECTIVE: To determine whether leptin is involved in bone remodeling in patients with
postmenopausal osteoporosis. DESIGN: Cross-sectional study. SETTING: Department of …

Objective: Present study was designed to find out whether leptin is a predictor of bone mass
density (BMD) in premenopausal women (PMW) and postmenopausal osteoporotic women …

OBJECTIVES: Bisphenol A (BPA) exposure may promote obesity, but its effect on bone
mineral density (BMD) has not been reported in humans. We aimed to examine the …